Aflibercept
Indication
Macular oedema secondary to central retinal vein occlusion (NICE TA305)
Red
Brand:
Eylea®
Nice TA:
305
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Eye
Background
Aflibercept solution for injection is recommended as an option for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion only if the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme.